Catalog No.
YHF09602
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
[Thr137-Thr155] & [Cys253-Val323]
Predicted molecular weight
25.71 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P55087
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Aquaporin-4, AQP-4, Mercurial-insensitive water channel, MIWC, WCH4, AQP4
Blood-brain barrier dysfunction in hepatic encephalopathy: pathophysiology, diagnostic assessment and therapeutic perspectives., PMID:40512384
DAGLA autoantibody experience at Mayo Clinic., PMID:40512252
Melatonin Enhances Aquaporin 4 and Alpha-Syntrophin Interaction by Inhibiting Cyclin-Dependent Kinase 5 Activity to Preserve Glymphatic Function in Neonatal Hypoxic-Ischemic Encephalopathy., PMID:40506855
Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica., PMID:40506785
Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders., PMID:40506618
Silent burden: recognising and managing invisible symptoms in neuromyelitis optica., PMID:40506118
Relapsing anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder diagnosed double positive for anti-myelin oligodendrocyte glycoprotein antibody., PMID:40506104
Uncovering the invisible giant: Amyloid ß plaques and their proposed association with waste removal in Alzheimer-affected human hippocampus., PMID:40501787
Oligodendroglia in Neuromyelitis Optica Spectrum Disorder., PMID:40500507
Astroglial Kir4.1 and AQP4 Channels: Key Regulators of Potassium Homeostasis and Their Implications in Autism Spectrum Disorders., PMID:40498219
Aquaporin-4-Mediated Water Permeability Rescues Aquaporin-3 Deficiency Caused Nephrogenic Diabetes Insipidus., PMID:40497427
The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD., PMID:40495001
Aquaporin-4 Peptide Injection in Mice Induces Retinal and Optic Nerve Alterations That Simulate Those of Neuromyelitis Optica Spectrum Disorder., PMID:40492995
Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: A Cohort Study., PMID:40492601
Rituximab as First-Line Compared to Escalation Immunotherapy Is Associated With Lower Disability Accumulation in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Cohort Study From Germany and the United Kingdom., PMID:40492480
Dual BLyS/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report., PMID:40491913
A Comprehensive Approach to Differentiating Systemic Lupus Erythematosus From Other Autoimmune Diseases Presenting With Optic Neuritis., PMID:40486405
Comorbidities Are Associated With Unfavorable Outcome in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Exploratory Study From the CROCTINO Cohort., PMID:40485599
Targeting TRPV4 to restore glymphatic system function and alleviate cerebral edema in ischemic stroke., PMID:40481713
Combination astragaloside IV and artesunate preserves blood-brain barrier integrity by modulating astrocytes and tight junction proteins in Plasmodium yoelii infection., PMID:40466596
A Differential Proteomic Analysis on Patient Sera with Neuromyelitis Spectrum Disorders (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) Suggested Shared and Distinct Disease Mechanisms., PMID:40464632
Functional and Clinical Relevance of the Crosstalk between the Glymphatic System and the Lymphatic System., PMID:40464180
Sex-dependent blood-brain barrier alterations following repeated mild blast traumatic brain injury at varying inter-injury intervals., PMID:40451452
Oedematic-atrophic astrocytes in hepatic encephalopathy., PMID:40450333
From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis., PMID:40447786
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study., PMID:40442445
Early neuromyelitis optica antibody-induced molecular changes in aquaporin 4 and associated proteins at astrocyte endfeet in murine brain tissues., PMID:40436483
The lncRNA 74.1/miR-324-3p/NRG1 axis as a differential diagnostic and prognostic biomarker in neuromyelitis optica and multiple sclerosis., PMID:40436286
A Case Report of Neuromyelitis Optica Spectrum Disorder in a Young Patient With Systemic Lupus Erythematosus., PMID:40432657
Trifluoperazine improves postoperative cognition by influencing astrocyte endfoot morphology and aquaporin-4 polarity., PMID:40425909
AQP-4 autoantibodies as potential early diagnostic biomarkers for NEC., PMID:40424658
The glymphatic system was impaired in spontaneously hypertensive rats., PMID:40419570
Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder., PMID:40415648
Protective effects of AER-271 in acute-phase radiation-induced brain injury in rats: reduction of brain edema, inflammation, apoptosis and maintenance of blood-brain barrier integrity., PMID:40406486
Aquaporin 4 and its isoforms regulation ameliorate AQP4 Mis-localization-induced glymphatic dysfunction in ischemic stroke., PMID:40403843
Selective removal of astrocytic PERK protects against glymphatic impairment and decreases toxic aggregation of β-amyloid and tau., PMID:40403715
Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity., PMID:40403514
Aggressive and Refractory Attack of AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder Treated With Ravulizumab: A Case Report., PMID:40400837
Co-occurrence of Down Syndrome and Multiple Sclerosis., PMID:40395918
Advances in biomarkers for optic neuritis and neuromyelitis optica spectrum disorders: a multi-omics perspective., PMID:40395766
Blood-brain barrier leakage in renovascular hypertensive rats: A quantitative MRI analysis., PMID:40393574
Pro-Inflammatory Molecules Implicated in Multiple Sclerosis Divert the Development of Human Oligodendrocyte Lineage Cells., PMID:40393021
Relaxin-2 Ameliorates Spinal Cord Injury by Inhibiting Microglia Activation., PMID:40392018
Relationships between neuropsychiatric symptoms, subtypes of astrocyte activities, and brain pathologies in Alzheimer's disease and Parkinson's disease., PMID:40390204
Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder., PMID:40380029
Experimental study of cerebral edema and expression of VEGF and AQP4 in the penumbra area of rat brain trauma., PMID:40379765
Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan., PMID:40377800
Detrimental Roles of Innate Immune cells in Neuromyelitis Optica Spectrum Disorder: Pathogenesis and Therapeutic Targeting., PMID:40377013
Neuroprotective effects of human umbilical cord mesenchymal stem cells (Neuroncell-EX) in a rat model of ischemic stroke are mediated by immunomodulation, blood-brain barrier integrity, angiogenesis, and neurogenesis., PMID:40360812
Anti-IL-6 receptor antibody suppresses onset of paralytic symptoms in AQP4 peptide-immunized mice without lowering bone strength or mineral density., PMID:40359583
For research use only. Not for human or drug use.
